BCL2 and neoplasm: This may indicate combination therapy enhances cell’s capacity to react to an apoptotic signal confirmed by the intracellular Bax/Bcl-2 ratio that acts as prognostic indicator for tumor aggressiveness, progression and assesses a cell’s propensity for apoptosis74–76,154,155.